Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.

Immunotherapy - 1 Aug 2020

Wu Richard C, Newman William, Patanowitz Liron, Branstetter Barton F, Amankulor Nduka, Tarhini Ahmad A

Abstract excerpt

Background: Leptomeningeal disease (LMD) from melanoma is rapidly fatal with median overall survival between 6.9 weeks and 3.5 months. It is not known whether immune checkpoint inhibitors have a role in treating LMD. Case presentation: We report a 33-year-old male patient who developed LMD from a BRAF V600E-mutated melanoma brain metastasis, despite prior treatment with surgical resection, radiotherapy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatal Outcome

Share to Melanoma

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Share to Remission Induction

Share to Spinal Cord Diseases

Source

Open in PubMed Open full text

Identifiers

PMID: 32571131
DOI: 10.2217/imt-2019-0004
PMCID: PMC7421879

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient.PMID 32571131Read ↗

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.Semantic proximity Read ↗

Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity Read ↗

Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal diseaseSemantic proximity Read ↗

Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.Semantic proximity Read ↗

Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy.Semantic proximity Read ↗

Unraveling the Enigma of Melanoma Brain Metastasis: New Horizons in Mechanisms, Diagnosis, and TherapySemantic proximity Read ↗

Treatment of leptomeningeal spread of NSCLC: a continuing challenge.Semantic proximity Read ↗

Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review.Semantic proximity Read ↗

Melanoma brain metastasis: overview of current management and emerging targeted therapies.Semantic proximity Read ↗

[Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis].Semantic proximity Read ↗

Efficacy of osimertinib combined with anti-VEGF therapy ramucirumab in managing leptomeningeal metastasis in EGFR-mutant NSCLC: a case report and literature review.Semantic proximity Read ↗

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.